BKM120 in Cancers With PIK3CA Activating Mutations

This study has been terminated.
(The study has been closed due to lack of accrual)
Sponsor:
Collaborator:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Jeffrey Engelman, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01501604
First received: December 27, 2011
Last updated: January 24, 2013
Last verified: January 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: December 2015
  Estimated Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)